Saturday 17 October 2026
Export MGX’s income statement to Excel — free account
Metagenomi Therapeutics, Inc.
In the quarter to June 2026, revenue fell 103.0%, EPS fell 35.2% and free cash flow grew 7.98%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.78
0.07
−8.24%
Follow MGX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 1.61 | 1.23 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 12.74 | 4.06 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 223 | 236 | 202 | 119 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.08 | 0.19 | 0.26 | 0.21 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 17 | 45 | 52 | 25 | ||||
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | (21) | (41) | (60) | (84) | (88) | |||||
| EBT margin, % | — | — | — | — | — | (8,823.87) | (238.51) | (134.57) | (159.81) | (348.77) | |||||
| Net income | — | — | — | — | — | (21) | (44) | (68) | (78) | (88) | |||||
| Depreciation | — | — | — | — | — | 1 | 0 | (5) | (2) | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.07 | 5.06 | 13.14 | 1.58 | 0.68 | ||||
| Earnings | — | — | — | — | — | (6.58) | (12.82) | (20.05) | (2.36) | (2.36) | |||||
| Cash flow | — | — | — | — | — | 7.45 | 8.74 | (26.85) | (3.30) | (2.39) | |||||
| Capex | — | — | — | — | — | (0.89) | (4.11) | (2.88) | (0.09) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | 6.55 | 4.63 | (29.73) | (3.40) | (2.40) | |||||
| Book value | — | — | — | — | — | 13.49 | 79.90 | 63.19 | 7.11 | 4.26 | |||||
| Shares, m | — | — | — | — | — | 3 | 3 | 3 | 33 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 0.78 | 0.78 | 0.78 | 2.28 | 2.39 | |||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.51 | 0.38 | |||||
| EV/Sales | — | — | — | — | — | (4.60) | (4.60) | (4.60) | (1.89) | (2.78) | |||||
| EV/FCF | — | — | — | — | — | 2.03 | 2.03 | 2.03 | 0.88 | 0.78 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 24 | 30 | (91) | (109) | (89) | ||||
| Capex | — | — | — | — | — | (3) | (14) | (10) | (3) | (1) | |||||
| Free cash flow | — | — | — | — | — | 21 | 16 | (101) | (112) | (89) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 84 | 318 | 209 | 221 | 143 | ||||
| Total debt | — | — | — | — | — | 30 | — | — | — | — | |||||
| Net debt | — | — | — | — | — | (78) | (362) | (271) | (248) | (161) | |||||
| Shareholders’ equity | — | — | — | — | — | 44 | 272 | 215 | 235 | 159 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (15.67) | (17.52) | (22.64) | (32.20) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 81.50 | 65.00 | (157.26) | (44.67) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Metagenomi Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALGS Aligos Therapeutics, Inc. | $33.7M | — (loss-making) | — (loss-making) | +2,778.55% (above 0%: growing) | n/m | −59.81% (below 0%: shrinking) | 100.00% | (6.80%) | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $33.3M | 3.1× | — (loss-making) | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| BCTX BRIACELL THERAP | $32.8M | 1.5× | — | — | n/m | +0.21% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GNTA Genenta Science S.p.A. Unsponsored ADR | $32.3M | — | — | — | — | +35.94% (above 0%: growing) | 0.00% | — | Compare |
| MGX Metagenomi Therapeutics, Inc. | $31.9M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | |
| GRDX GridAI Technologies Corp. | $31.8M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NXTC NextCure, Inc. | $31.5M | — (loss-making) | — (loss-making) | +1,549.08% (above 0%: growing) | n/m | +57.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CVM Cel-Sci Corporation | $30.6M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNAZ TransCode Therapeutics Inc. | $30.5M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $32.0M | — | — | +2,163.82% | — | −3.62% | 0.00% | 0.00% |
Metagenomi Therapeutics, Inc. (MGX) key facts
- Metagenomi Therapeutics, Inc. (MGX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MGX traded at $0.78, a market capitalization of $31.9 million.
- Return on equity was −44.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −1.93 (distress zone) for fiscal 2025.